ReviewHealth economics review2024
Evaluating the costs of adverse drug events in hospitalized patients: a systematic review.
Review in Health economics review, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hospitalisation as an Opportunity to Optimise Quality Use of Medicines in Older Adults: A Systematic Review.Drugs & aging · 2026Pooled it
- Nationwide validation of the CLEO tool to evaluate the relevance of pharmacists' interventions in German hospitals.International journal of clinical pharmacy · 2026Article
- Assessment of drug-related problems and associated factors among patients with chronic obstructive pulmonary disease in Dailekh, Nepal: a cross-sectional study.Scientific reports · 2026Article
- The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics-Based Clinical Guidelines.Clinical pharmacology and therapeutics · 2026Article
- Pharmacogenetics in Community Pharmacy: Global Perspectives and Implementation.Journal of clinical medicine · 2026Review
- Evolution of Computerized Provider Order Entry Documentation at a Leading Tertiary Care Referral Center in Riyadh.Healthcare (Basel, Switzerland) · 2026Article
- Informing the patient of the placebo option: an ethical necessity likely to reduce inappropriate psychotropic prescriptions?Therapeutic advances in psychopharmacology · 2026Review
- Article
- A Cost Analysis of Adverse Event Management of Systemic Therapies for Metastatic Colorectal Cancer on Patients with at Least Two Previous Lines of Treatment in Spain.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Medication Errors in Critical Care.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025Article
- AutoPK: Leveraging LLMs and a Hybrid Similarity Metric for Advanced Retrieval of Pharmacokinetic Data from Complex Tables and Documents.International Conference on Tools with Artificial Intelligence : [proceedings]. International Conference on Tools for Artificial Intelligence · 2025Article
- Identifying Adverse Drug Events in Clinical Text Using Fine-Tuned Clinical Language Models: Machine Learning Study.JMIR formative research · 2025Article
- Trends in adverse drug reaction reporting in eight selected countries after the implementation of new pharmacovigilance regulation in 2012: a joinpoint regression analysis.European journal of clinical pharmacology · 2025Article
- Probing the in-depth analysis of Serious Adverse Drug Reactions in a tertiary care hospital of Central India.Exploratory research in clinical and social pharmacy · 2025Article
- Probing Large Language Model Hidden States for Adverse Drug Reaction Knowledge.medRxiv : the preprint server for health sciences · 2025Article
- Pharmacist-led surgical medicines prescription optimization and prediction service improves patient outcomes - a machine learning based study.Frontiers in pharmacology · 2025Article
- Article
- Comparison of Intraoperative Fentanyl Usage and Waste After Transition from 100-μg Vials to 50-μg Preloaded Syringes: A Single-Center Retrospective Study.International journal of anesthesia and clinical medicine · 2024Article
- Potential Adverse Drug Events Identified with Decision Support Algorithms from Janusmed Risk Profile-A Retrospective Population-Based Study in a Swedish Region.Pharmacy (Basel, Switzerland) · 2024Article
- Deciphering the Intricate Interplay in the Framework of Antibiotic-Drug Interactions: A Narrative Review.Antibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdverse drug events (ADEs) are not only a safety and quality of care issue for patients, but also an economic issue with significant costs. Because they often occur during hospital stays, it is necessary to accurately quantify the costs of ADEs. This review aimed to investigate the methods to calculate these costs, and to characterize their nature.
methodsA systematic literature review was conducted to identify methods used to assess the cost of ADEs on Medline, Web of Science and Google Scholar. Original articles published from 2017 to 2022 in English and French were included. Economic evaluations were included if they concerned inpatients.
resultsFrom 127 studies screened, 20 studies were analyzed. There was a high heterogeneity in nature of costs, methods used, values obtained, and time horizon chosen. A small number of studies considered non-medical (10%), indirect (20%) and opportunity costs (5%). Ten different methods for assessing the cost of ADEs have been reported and nine studies did not explain how they obtained their values.
conclusionsThere is no consensus in the literature on how to assess the costs of ADEs, due to the heterogeneity of contexts and the choice of different economic perspectives. Our study adds a well-deserved overview of the existing literature that can be a solid lead for future studies and method implementation.
trial registrationPROSPERO registration CRD42023413071.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.